Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.

Pharmacogenomics - 1 Jun 2014

Hicks J Kevin, Crews Kristine R, Flynn Patricia, Haidar Cyrine E, Daniels Calvin C, Yang Wenjian, Panetta John C, Pei Deqing, Scott Jeffrey R, Molinelli Alejandro R, Broeckel Ulrich, Bhojwani Deepa, Evans William E, Relling Mary V

Abstract excerpt

AIM: Our objective was to describe the association between voriconazole concentrations and CYP2C19 diplotypes in pediatric cancer patients, including children homozygous for the CYP2C19*17 gain-of-function allele. MATERIALS & METHODS: A linear mixed effect model compared voriconazole dose-corrected trough concentrations (n = 142) among CYP2C19 diplotypes in 33 patients (aged 1-19 years). Voriconazole...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Child
Share to Child, Preschool

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2C19

Share to Haplotypes

Share to Homozygote

Share to Infant

Share to Pharmacogenetics

Share to Voriconazole

Source

Open in PubMed Open full text

Identifiers

PMID: 25084200
DOI: 10.2217/pgs.14.53
PMCID: PMC4155516

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Voriconazole plasma concentrations in immunocompromised pediatric patients vary by CYP2C19 diplotypes.PMID 25084200Read ↗

Pharmacogenetic implementation for CYP2C19 and pharmacokinetics of voriconazole in children with malignancy or inborn errors of immunity.Semantic proximity Read ↗

CYP2C19 Phenotype and Body Weight-Guided Voriconazole Initial Dose in Infants and Children after Hematopoietic Cell Transplantation.Semantic proximity Read ↗

Therapeutic drug monitoring and CYP2C19 genotyping guide the application of voriconazole in childrenSemantic proximity Read ↗

Correlation of CYP2C19 phenotype with voriconazole plasma concentration in children.Semantic proximity Read ↗

Impact of the CYP2C19 genotype on voriconazole exposure in adults with invasive fungal infections.Semantic proximity Read ↗

CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole.Semantic proximity Read ↗

Impact of CYP2C19 Phenotype and Drug-Drug Interactions on Voriconazole Concentration in Pediatric Patients.Semantic proximity Read ↗

Voriconazole therapeutic drug monitoring including analysis of CYP2C19 phenotype in immunocompromised pediatric patients with invasive fungal infections.Semantic proximity Read ↗

Impact of the CYP2C19*17 allele on the pharmacokinetics of omeprazole and pantoprazole in children: evidence for a differential effect.Semantic proximity Read ↗

Population Pharmacokinetics and Factors Influencing Trough Concentration of Voriconazole in Children with Hematological MalignanciesSemantic proximity Read ↗

Pharmacogenetic and clinical predictors of voriconazole concentration in hematopoietic stem cell transplant recipients receiving CYP2C19-guided dosing.Semantic proximity Read ↗

Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.